BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23451143)

  • 1. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.
    Dong Y; Stephens C; Walpole C; Swedberg JE; Boyle GM; Parsons PG; McGuckin MA; Harris JM; Clements JA
    PLoS One; 2013; 8(2):e57056. PubMed ID: 23451143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread.
    Loessner D; Rizzi SC; Stok KS; Fuehrmann T; Hollier B; Magdolen V; Hutmacher DW; Clements JA
    Biomaterials; 2013 Oct; 34(30):7389-400. PubMed ID: 23827191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma.
    Dong Y; Tan OL; Loessner D; Stephens C; Walpole C; Boyle GM; Parsons PG; Clements JA
    Cancer Res; 2010 Apr; 70(7):2624-33. PubMed ID: 20332224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.
    Loessner D; Quent VM; Kraemer J; Weber EC; Hutmacher DW; Magdolen V; Clements JA
    Gynecol Oncol; 2012 Dec; 127(3):569-78. PubMed ID: 22964375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
    Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
    Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell‑fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer.
    Han Q; Huang B; Huang Z; Cai J; Gong L; Zhang Y; Jiang J; Dong W; Wang Z
    Int J Mol Med; 2019 Dec; 44(6):2245-2255. PubMed ID: 31638162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
    Gong W; Liu Y; Seidl C; Dreyer T; Drecoll E; Kotzsch M; Bronger H; Dorn J; Magdolen V
    PLoS One; 2019; 14(2):e0212968. PubMed ID: 30811511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.
    Hirst J; Pathak HB; Hyter S; Pessetto ZY; Ly T; Graw S; Koestler DC; Krieg AJ; Roby KF; Godwin AK
    Cancer Res; 2018 Aug; 78(15):4370-4385. PubMed ID: 29891506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
    Gunay G; Kirit HA; Kamatar A; Baghdasaryan O; Hamsici S; Acar H
    Gynecol Oncol; 2020 Nov; 159(2):563-572. PubMed ID: 32958270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
    Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
    Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
    Correa RJ; Valdes YR; Peart TM; Fazio EN; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
    Carcinogenesis; 2014 Sep; 35(9):1951-61. PubMed ID: 24562574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic Voyage of Ovarian Cancer Cells in Ascites with the Assistance of Various Cellular Components.
    Uno K; Iyoshi S; Yoshihara M; Kitami K; Mogi K; Fujimoto H; Sugiyama M; Koya Y; Yamakita Y; Nawa A; Kanayama T; Tomita H; Enomoto A; Kajiyama H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.
    Shahinian H; Loessner D; Biniossek ML; Kizhakkedathu JN; Clements JA; Magdolen V; Schilling O
    Mol Oncol; 2014 Feb; 8(1):68-82. PubMed ID: 24120346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
    Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
    Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KLK4 Inhibition by Cyclic and Acyclic Peptides: Structural and Dynamical Insights into Standard-Mechanism Protease Inhibitors.
    Riley BT; Ilyichova O; de Veer SJ; Swedberg JE; Wilson E; Hoke DE; Harris JM; Buckle AM
    Biochemistry; 2019 May; 58(21):2524-2533. PubMed ID: 31058493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.
    Kryza T; Silva LM; Bock N; Fuhrman-Luck RA; Stephens CR; Gao J; Samaratunga H; ; Lawrence MG; Hooper JD; Dong Y; Risbridger GP; Clements JA
    Mol Oncol; 2017 Oct; 11(10):1307-1329. PubMed ID: 28510269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
    He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
    Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids.
    Correa RJ; Peart T; Valdes YR; DiMattia GE; Shepherd TG
    Carcinogenesis; 2012 Jan; 33(1):49-58. PubMed ID: 22045027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.